HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
INCR
InterCure Ltd.
There isn't enough reported data to score INCR yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
INCR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Healthy |
INCR's balance sheet is currently healthy, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
INCR PE Valuation
INCR has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
INCR Forward outlook
There aren't enough analyst estimates for INCR to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
INCR has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus INCR down 195%.
INCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$2.32 | -$0.18 |
| Q4 2023 | -$2.14 | -238% |
| Q4 2022 | $1.55 | +812% |
| Q4 2021 | $0.17 | +$2.61 |
| Q4 2020 | -$2.44 | -$2.25 |
| Q3 2020 | -$3.93 | -1059% |
| Q2 2020 | -$5.04 | -567% |
| Q1 2020 | -$5.75 | -459% |
INCR is still losing money, but far less than before: $2.32 per share over the past year, against $5.75 at its worst in early 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
INCR has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus up 782% for INCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
INCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $75M | -33% |
| Q4 2023 | $111.7M | -8.5% |
| Q4 2022 | $122.1M | +77% |
| Q4 2021 | $69M | +711% |
| Q4 2020 | $8.5M | +1382% |
| Q3 2020 | $7.1M | +766% |
| Q2 2020 | $3.5M | +303% |
| Q1 2020 | $1.3M | +147% |
INCR's revenue has grown year over year for 12 quarters in a row: $75M last quarter, up 782% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -28% | -56 points |
| Q4 2023 | -12% | -22 points |
| Q4 2022 | 13% | +21 points |
| Q4 2021 | 13% | +1125 points |
| Q4 2020 | 28% | +765 points |
| Q3 2020 | 11% | +566 points |
| Q2 2020 | -7.6% | +363 points |
| Q1 2020 | -1113% | -3300 points |
INCR's operating margin was −28% last quarter, down 56 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the stronger cash trend. Its trailing FCF is down 84% versus its history, compared with INCR at down 3,189%.
INCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$22.4M | -$4.7M |
| Q4 2023 | -$17.7M | -278% |
| Q4 2022 | $9.9M | +187% |
| Q4 2021 | $3.5M | +136% |
| Q4 2020 | $1.5M | -84% |
| Q3 2020 | $525.2K | +$5.5M |
| Q2 2020 | -$2.9M | +$1.4M |
| Q1 2020 | -$3.1M | -$2.3M |
INCR has burned cash in most quarters: −$27M over the past year, against −$4M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over INCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
INCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +59.3K shares |
| 1 year | +81% | +4.1M shares |
| 3 years | +138% | +5.3M shares |
| 5 years | +256% | +6.6M shares |
| Available history | +344% | +7.1M shares |
INCR has 9M diluted shares, up 81% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
| Q1 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
INCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -0.1x | Net Cash |
| Q4 2021 | -3.2x | Net Cash |
| Q4 2020 | -3.7x | Net Cash |
| Q3 2019 | -0.4x | Net Cash |
| Q2 2019 | -2.1x | Net Cash |
| Q1 2019 | 0.3x | Very low |
| Q4 2016 | -0.4x | Net Cash |
INCR has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
INCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 13.5 | Oversold |
INCR's weekly RSI is 42 (neutral) and its Stochastic is 14 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
INCR PE vs Healthcare Sector
| Metric | INCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
INCR has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
INCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.54 | 12% below |
| 20 week MA | $4.83 | 18% below |
| 50 week MA | $4.77 | 17% below |
| 100 week MA | $6.21 | 36% below |
| 200 week MA | $8.06 | 51% below |
INCR is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
INCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.45 | $6.00 | +10% |
| 2021 | $6.00 | $36.0 | +500% |
| 2022 | $36.0 | $19.2 | -47% |
| 2023 | $19.2 | $6.45 | -66% |
| 2024 | $6.45 | $8.15 | +26% |
| 2025 | $8.15 | $5.65 | -31% |
| 2026 YTD | $5.65 | $3.98 | -30% |
INCR has the edge over HIMS on returns for 2026, with the stronger performance.